Septerna (NASDAQ:SEPN) Trading Down 3.9% - Time to Sell?

Key Points

• Septerna, Inc. (NASDAQ:SEPN) saw its stock price decline by 3.9%, trading at $14.15, with a significant drop in trading volume of 91% compared to average volumes.
• Analysts have varied opinions on Septerna, with ratings including a hold from Wall Street Zen, an overweight target from Cantor Fitzgerald at $25.00, and a buy recommendation from HC Wainwright with a $26.00 price objective.
• The company's recent earnings report showed a loss of ($0.56) EPS, missing expectations significantly, with projected earnings for the current fiscal year expected to remain negative at -7.11 EPS.

Septerna, Inc. (NASDAQ:SEPN - Get Free Report) shares traded down 3.9% during mid-day trading on Thursday . The company traded as low as $14.27 and last traded at $14.15. 60,214 shares traded hands during trading, a decline of 91% from the average session volume of 642,776 shares. The stock had previously closed at $14.72.

Analysts Set New Price Targets

Several brokerages have commented on SEPN. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price objective on shares of Septerna in a research report on Friday, September 5th. HC Wainwright reaffirmed a "buy" rating and issued a $26.00 price target on shares of Septerna in a research note on Thursday, August 21st. Finally, Wall Street Zen cut shares of Septerna from a "hold" rating to a "sell" rating in a research report on Saturday. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $26.75.

Septerna Stock Performance

The business has a 50-day moving average price of $12.54 and a 200-day moving average price of $9.51.

Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.51). Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $22.50 million. On average, research analysts forecast that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Septerna

Institutional investors have recently bought and sold shares of the business. Rangeley Capital LLC raised its stake in Septerna by 10.7% in the second quarter. Rangeley Capital LLC now owns 58,605 shares of the company's stock worth $619,000 after buying an additional 5,655 shares in the last quarter. Perceptive Advisors LLC bought a new position in shares of Septerna in the 2nd quarter worth $5,723,000. Boothbay Fund Management LLC bought a new position in shares of Septerna in the 2nd quarter worth $255,000. Bank of America Corp DE lifted its stake in shares of Septerna by 758.3% during the 2nd quarter. Bank of America Corp DE now owns 99,213 shares of the company's stock worth $1,049,000 after purchasing an additional 87,654 shares during the last quarter. Finally, VR Adviser LLC bought a new stake in Septerna during the second quarter valued at about $5,713,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.